Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Moodys
McKesson
Colorcon
McKinsey

Last Updated: August 8, 2022

Investigational Drug Information for Gossypol


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Gossypol?

Gossypol is an investigational drug.

There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Glioblastoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Sidney Kimmel Comprehensive Cancer Center.

There is one US patent protecting this investigational drug and eight international patents.

Recent Clinical Trials for Gossypol
TitleSponsorPhase
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNational Cancer Institute (NCI)Phase 1
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaMayo ClinicPhase 1
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1/Phase 2

See all Gossypol clinical trials

Clinical Trial Summary for Gossypol

Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol

See all Gossypol clinical trials

US Patents for Gossypol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gossypol See Plans and Pricing Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA) See Plans and Pricing
Gossypol See Plans and Pricing Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) See Plans and Pricing
Gossypol See Plans and Pricing Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) See Plans and Pricing
Gossypol See Plans and Pricing Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gossypol

Drugname Country Document Number Estimated Expiration Related US Patent
Gossypol Australia AU2014232383 2033-03-15 See Plans and Pricing
Gossypol Australia AU2019202731 2033-03-15 See Plans and Pricing
Gossypol Australia AU2019288275 2033-03-15 See Plans and Pricing
Gossypol Brazil BR112015023267 2033-03-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Moodys
McKesson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.